KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Gilead Sciences (GILD) Long-Term Deferred Tax (2016 - 2025)

Gilead Sciences (GILD) has disclosed Long-Term Deferred Tax for 11 consecutive years, with $2.0 billion as the latest value for Q3 2025.

For the quarter ending Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $2.0 billion, compared with a TTM value of $2.0 billion through Sep 2025, changed N/A, and an annual FY2024 reading of $2.4 billion, changed N/A over the prior year.
Long-Term Deferred Tax was $2.0 billion for Q3 2025 at Gilead Sciences, down from $2.7 billion in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $2.7 billion in Q2 2025 and bottomed at $2.0 billion in Q3 2025.